SCHEMBL20111217

SCHEMBL20111217

CCOc1ccc2c(c1F)-c1c-2cc(-c2ccccc2F)c(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
FGFR2 P21802 2/20 0.38
PTPRC P08575 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
KCNN4 O15554 1/20 0.35
FGFR1 P11362 1/20 0.35
PKM P14618 1/20 0.35
GAA P10253 2/20 0.34
MEN1 O00255 1/20 0.34
APAF1 O14727 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20111542 0.84 ADORA3 (0.39) L3MBTL1ALDH1A1KDM4EFGFR2PTPRC
SCHEMBL20111597 0.79 S1PR1 (0.44) L3MBTL1FGFR2PTPRCNPC1RAB9A
SCHEMBL20102438 0.79 RARB (0.37) L3MBTL1NPC1RAB9AMEN1APAF1
SCHEMBL20102414 0.78 FGFR2 (0.39) L3MBTL1ALDH1A1KDM4EFGFR2PTPRC
SCHEMBL20111323 0.77 FGFR2 (0.45) L3MBTL1ALDH1A1FGFR2PTGS1PTGS2
SCHEMBL20111640 0.77 HTR1A (0.45) L3MBTL1ALDH1A1KDM4ENPC1LMNA
SCHEMBL20111651 0.77 FGFR2 (0.38) ALDH1A1FGFR2NPC1RAB9APTGS1
SCHEMBL2508922 0.76 L3MBTL1 (0.46) L3MBTL1ALDH1A1KDM4EFGFR2PTPRC
SCHEMBL10019961 0.75 PTPRC (0.41) L3MBTL1ALDH1A1KDM4EFGFR2PTPRC
SCHEMBL20102404 0.74 CTSL (0.39) L3MBTL1ALDH1A1KDM4EFGFR2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S L3MBTL1 177/4885ALDH1A1 1182/4885KDM4E 1555/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S L3MBTL1 177/4885ALDH1A1 1182/4885KDM4E 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.